As scholars delve deeper into radiomics, increasing evidence suggests that PEF/CT radiomics may be used to investigate the molecular biological characteristics of tumors, such as PD-1/PD-L1 expression and tumor mutation burden, thereby providing a new approach for assessing the effectiveness of immunotherapy and predicting patient prognosis [45, 46]. The gene discussed is CD274; the disease is neoplasm.